ciltacabtagene autoleucel
janssen
['cartitude 2', 'mmsm']
impressive durability of response from early data of cartitude 2 for patients that relapse &lt;12 months from asct. 40% progressed through bridging therapy. #eha22 #mmsm 
Haematologist @uclh, associate professor @ucl. Chair NCRI Myeloma Group (UK Myeloma Research Alliance). All views are my own.